Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Table 4 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) and non-inflammatory diseases of the CNS (N-INF) after data reduction with PCA

	Disease	Predicted Group Membership^b.c		Total
	Disease	RRMS	N-INF	Total
Original
Count	RRMS	66	3	69
Count	N-INF	13	29	42
%	RRMS	95.7	4.3	100
%	N-INF	31.0	69.0	100
Cross-validated^a
Count	RRMS	66	3	69
Count	N-INF	13	29	42
%	RRMS	95.7	4.3	100
%	N-INF	31.0	69.0	100

^aCross-validation is done only for those sets of samples analyzed. In cross-validation, each sample is classified by the functions derived from all samples other the one under analysis
^b85.6% of original grouped samples correctly classified
^c85.6% of cross-validated grouped samples correctly classified

ISSN: 1742-2094